easysep human cd2 positive selection kit ii (STEMCELL Technologies Inc)
90
Structured Review
STEMCELL Technologies Inc
easysep human cd2 positive selection kit ii
Easysep Human Cd2 Positive Selection Kit Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd2+selection+kit/easysep+human+t+cell+isolation+kit/pmc12146614-81-0-8
Average 90 stars, based on 1 article reviews
Easysep Human Cd2 Positive Selection Kit Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd2+selection+kit/easysep+human+t+cell+isolation+kit/pmc12146614-81-0-8
Average 90 stars, based on 1 article reviews
easysep human cd2 positive selection kit ii - by Bioz Stars,
2026-10
90/100 stars
Images
1) Product Images from "Second generation CD2-targeting LFA-3 fusion protein SBT115301 to restore immune homeostasis in autoimmune disease"
Article Title: Second generation CD2-targeting LFA-3 fusion protein SBT115301 to restore immune homeostasis in autoimmune disease
Journal: iScience
doi: 10.1016/j.isci.2025.112447
Figure Legend Snippet: Sequence alignment of the engineered CD2 binding domain of SBT115301 with human WT LFA-3 Yellow boxes denote amino acids identified as being involved in binding to CD2, with white, gray, and black dots showing the effects of single amino acid mutagenesis on binding of human LFA-3 to human CD2. Red arrows and boxes identify residues that were altered in SBT115301.
Techniques Used: Sequencing, Binding Assay, Mutagenesis
Figure Legend Snippet: SBT115301 preferentially depletes CD2 hi -expressing T cells in vitro (A) Median fluorescence intensity (MFI) of CD2 expression on NK cells (CD3 − CD56 + ) and CD3 + CD4 + T reg (CD25 hi FOXP3 + T n (CD45RA + CCR7 + ), T cm (CD45RA − CCR7 + ), and T em (CD45RA − CCR7 - ) cell subsets ( n = 30). Boxes represent the interquartile range (25th to 75th percentile). Individual data points are shown. (B) Activation of the high affinity (V158; each condition in triplicate, 5 experiments) and low affinity (F158; each condition in triplicate, 4 experiments) CD16a variants by SBT115301 as measured by mean ± SD relative light units (RLU) in a Jurkat ADCC reporter assay. (C) Representative histogram demonstrating the difference in CD2 expression of a PBMC sample incubated for 20 h with 100 nM SBT115301 or control (left). PBMC were incubated with increasing concentrations of SBT115301 or control in triplicate and mean ± SD cell numbers were quantified at the end of the assay (right). (D) Mean ± SD cell counts normalized to no test or control added of naive (CD45RA + ) and proliferating (Prolif) and non-proliferating (Non-prolif) memory (CD45RO + ) CD4 + T cells following incubation of CMV-reactive PBMC with CMV antigen and SBT115301 for 6 days. Each condition run in triplicate. Wilcoxon rank-sum ∗∗∗∗ p ≤ 0.001 by Wilcoxon rank-sum test (A).
Techniques Used: Expressing, In Vitro, Fluorescence, Activation Assay, Reporter Assay, Incubation, Control
Figure Legend Snippet: SBT115301 depletes T cell subsets with higher CD2 expression in an NHP model (A) Comparison of ADCC activity of SBT115301 in human versus non-human primate (NHP) in a primary PBMC in vitro assay. Boxes represent the interquartile range (25th to 75th percentile). Individual data points are shown. (B and C) Mean ± SD numbers of (B) circulating total (CD3 + ) T cells, CD4 + T cells, and CD8 + T cells, (C) CD4 + T em (CD45RA − CCR7 - ), T cm (CD45RA − CCR7 + ), T n (CD45RA + CCR7 + ), and T reg (CD4 + CD25 hi FOXP3 + ) expressed as % of baseline (pre-dose) cell counts after a single dose of SBT115301. (D) Mean ± SD numbers of circulating (CD3 + ) T cells in combined male and female NHP in a multi-dose (weekly) study. Data were collected pre-treatment (pre-Tx; Day 1) and up to 168 h post-Dose 1 ( n = 5 animals/sex/group), pre-Dose 5 (Day 29) and up to 168 h post-Dose 5 ( n = 5 animals/sex/group), and at the end of the study (Day 92; n = 2 animals/sex/group). (E) Mean ± SD anti-drug antibody (ADA) titers in NHP receiving multiple doses of SBT115301.
Techniques Used: Expressing, Comparison, Activity Assay, In Vitro
Figure Legend Snippet: Safety, PK, and ADA profiles of a single dose of SBT115301 in healthy participants (A) Mean ± SD numbers of circulating CD4 + T cells over time in participants that received SBT115301 or placebo expressed as absolute counts (left) and as % of baseline (pre-dose; right). (B) PK of SBT115301 as demonstrated by the mean ± SD serum concentration of SBT115301 in participants over time. (C) Mean ± SD ADA titers of ADA + participants over time. (D) The effects of ADA on PK as measured by dose normalized AUC inf (left) and on PD as measured by the decrease of T em from baseline at days 36 and 72 post-dose (right). Boxes represent the interquartile range (25th to 75th percentile). Individual data points are shown. (E) The effect of ADA + serum on SBT115301-mediated ADCC activity as measured by a Jurkat ADCC-reporter assay, comparing pre-dose and Day 72 serum samples (left), and correlated with ADA titer (right). Boxes represent the interquartile range (25th to 75th percentile); individual data points are shown (left). Blue lines and gray shades (right) are loess smooth lines with the associated 95% confidence bands. (F) The effect of ADA + serum in a Jurkat activation reporter assay examining activation of Jurkat cells following binding of recombinant LFA-3 protein to Jurkat-expressed CD2. Boxes represent the interquartile range (25th to 75th percentile). Individual data points are shown. (G) The differential binding of ADA + serum to CD2-binding domains of SBT115301 and WT LFA-3. Boxes represent the interquartile range (25th to 75th percentile); individual data points are shown. Lines connect paired measurements from the same donor at pre-treatment and D72 timepoints.
Techniques Used: Concentration Assay, Activity Assay, Reporter Assay, Activation Assay, Binding Assay, Recombinant
Figure Legend Snippet: Pharmacodynamics of a single dose of SBT115301 in healthy participants (A) Mean ± SD numbers of circulating CD4 + T em (CD45RA − CCR7 - ), T cm (CD45RA − CCR7 + ), and T n (CD45RA + CCR7 + ) subsets reported as % change of pre-treatment values over time. (B and C) Maximum reduction of (B) CD4 + T em and (C) T reg (CD4 + CD127 lo CD25 hi FOXP3 + ) in each cohort reported in % change from baseline as measured by the net area under the effect curve from Day 3 to Day 8 using % change from baseline based on cell counts divided by duration of time (E avg(3-8) ). Boxes represent the interquartile range (25th to 75th percentile). One-way analysis of variance and Dunnett’s test were used to compare between treated groups and placebo groups. Statistical significance (compared to placebo) was set at ns, p > 0.05; ∗, p < 0.05; ∗∗, p < 0.01. (D) Mean ± SD ratio of T reg to T em cells reported as a % change of pre-treatment values following dosing in the 10 and 30 mg IM cohorts compared to participants who received placebo. (E) Durability of the CD4 + T em PD response at timepoints after 32 days compared to the initial PD response measured by E avg(3-8) . (F) Correlation of baseline CD2 median fluorescence intensity on all cell subsets tested (CD4 + and CD8 + T cell subsets) with the PD responses of each subset as measured by E avg(3-36) . Linear regressions were used to depict relations between E avg(3-36) and baseline CD2 median fluorescence intensity within each dose. Fitted regression lines (solid lines) with 95% confidence bands (dotted lines) are displayed. Colored dots represent estimated E avg(3-36) for each cell subset at the average CD2 level and vertical edges represent 95% confidence intervals. ∗ p < 0.05, ∗∗ p < 0.01, ns (not significant) by one-way analysis of variance and Dunnett’s test (B and C).
Techniques Used: Drug discovery, Fluorescence
Related Articles
Selection:Article Title: Protocol for phenotyping and isolation of dendritic cell subsets from blood and lymphoid organs of non-human primates and humans by flow cytometry Article Snippet: .. Magnetic depletion of unwanted populations using StemCell Article Title: A CARMIL2 gain-of-function mutation suffices to trigger most CD28 costimulatory functions in vivo Article Snippet: Jurkat T cells were analyzed using anti-CD3 (OKT3), anti-CD28 (CD28.2), and anti-CD69 (FN50), all from BD. .. CD4 + and CD8 + T cells were purified by immunomagnetic negative selection using CD4 or Article Title: CD56 on intratumoral NK cells: orchestrating NK cell-mediated anti-tumor effects in bladder cancer Article Snippet: .. To ensure a completely homogeneous T24-CD56KO cell line, the single colonies were depleted using the Article Title: Sustained and specific multiplexed immune checkpoint modulation in CAR T cells induced by targeted epigenome editing Article Snippet: Peripheral blood mononuclear cells (PBMCs) from at least three different healthy donors were obtained from leukoreduction system (LRS) chambers by density gradient separation using Biocoll (Bio&SELL, Nuremberg, Germany). .. Primary T cells were obtained from PBMCs either by enrichment after activation or by negative selection using the Article Title: Protocol for phenotyping and isolation of dendritic cell subsets from blood and lymphoid organs of non-human primates and humans by flow cytometry Article Snippet: LIVE/DEAD fixable blue dead , Fisher Scientific , Cat# 10114812. .. other:Article Title: Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models Article Snippet: Human monocytes were isolated from peripheral blood ( Article Title: Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations Article Snippet: Plates were incubated for 10 min and luminescence was measured with a SpectraMax i3 plate reader (Molecular Device). Article Title: A CARMIL2 gain-of-function mutation suffices to trigger most CD28 costimulatory functions in vivo Article Snippet: Naive CD8 + T cells were purified from OT-I, OT-I Carmil 2 −/− , and OT-I Carmil2 QE mice by immunomagnetic negative selection using Purification:Article Title: A CARMIL2 gain-of-function mutation suffices to trigger most CD28 costimulatory functions in vivo Article Snippet: Jurkat T cells were analyzed using anti-CD3 (OKT3), anti-CD28 (CD28.2), and anti-CD69 (FN50), all from BD. .. CD4 + and CD8 + T cells were purified by immunomagnetic negative selection using CD4 or Cell Isolation:Article Title: A CARMIL2 gain-of-function mutation suffices to trigger most CD28 costimulatory functions in vivo Article Snippet: Jurkat T cells were analyzed using anti-CD3 (OKT3), anti-CD28 (CD28.2), and anti-CD69 (FN50), all from BD. .. CD4 + and CD8 + T cells were purified by immunomagnetic negative selection using CD4 or Article Title: Sustained and specific multiplexed immune checkpoint modulation in CAR T cells induced by targeted epigenome editing Article Snippet: Peripheral blood mononuclear cells (PBMCs) from at least three different healthy donors were obtained from leukoreduction system (LRS) chambers by density gradient separation using Biocoll (Bio&SELL, Nuremberg, Germany). .. Primary T cells were obtained from PBMCs either by enrichment after activation or by negative selection using the Activation Assay:Article Title: Sustained and specific multiplexed immune checkpoint modulation in CAR T cells induced by targeted epigenome editing Article Snippet: Peripheral blood mononuclear cells (PBMCs) from at least three different healthy donors were obtained from leukoreduction system (LRS) chambers by density gradient separation using Biocoll (Bio&SELL, Nuremberg, Germany). .. Primary T cells were obtained from PBMCs either by enrichment after activation or by negative selection using the |
